Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T12:46:21.905Z.
Calculation as of: 2026-10-06T12:46:21.905Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f06204e81c8a2ed41a5798160e844c591f5150b644efe168084329023db9ebc4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
DiaMedica Therapeutics Inc.
Market Cap
$453.70M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$450.64M
Free Cash Flow Yield
N/A
TTM Avg
28.70%
3Y Avg
28.70%
5Y Avg
28.70%
Market Cap
$447.43M
Free Cash Flow Yield
N/A
TTM Avg
4.98%
3Y Avg
4.98%
5Y Avg
4.98%
Market Cap
$471.57M
Free Cash Flow Yield
N/A
TTM Avg
1.11%
3Y Avg
1.42%
5Y Avg
1.42%
Market Cap
$478.54M
Free Cash Flow Yield
N/A
TTM Avg
3.93%
3Y Avg
3.93%
5Y Avg
3.93%
Market Cap
$428.16M
Free Cash Flow Yield
N/A
TTM Avg
2.75%
3Y Avg
2.75%
5Y Avg
2.75%
Market Cap
$481.33M
Free Cash Flow Yield
N/A
TTM Avg
18.77%
3Y Avg
18.69%
5Y Avg
14.04%
Market Cap
$487.30M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | $453.70M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | N/A | 28.70% | 28.70% | 28.70% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | N/A | 4.98% | 4.98% | 4.98% |
| NRC Health (NRC)vs › | $468.31M | 4.62% | 3.79% | 3.99% | 3.71% |
| Cerus Corporation (CERS)vs › | $471.57M | N/A | 1.11% | 1.42% | 1.42% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | N/A | 3.93% | 3.93% | 3.93% |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | N/A | 2.75% | 2.75% | 2.75% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | N/A | 18.77% | 18.69% | 14.04% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $487.30M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | N/A | 13.37% | 10.70% | 10.70% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
